These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15052374)

  • 21. Effect of IFN-alpha on total haemolytic activity of CH50 complement system and C3, C4 levels in children with chronic hepatitis C.
    Woźniakowska-Gesicka T; Wiśniewska-Ligier M; Kupś J
    Med Sci Monit; 2001 May; 7 Suppl 1():202-6. PubMed ID: 12211720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement Factor 3 Could Be an Independent Risk Factor for Mortality in Patients with HBV Related Acute-on-Chronic Liver Failure.
    Zhang GL; Zhang T; Ye YN; Liu J; Zhang XH; Xie C; Peng L; Gao ZL
    Biomed Res Int; 2016; 2016():3524842. PubMed ID: 27144164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of nizofenone on the symptomatic vasospasm after aneurysmal subarachnoid hemorrhage and its relationship to the levels of serum complements (CH50, C3 and C4)].
    Ogata N; Yonekawa Y; Kawano T; Tsukahara T
    Nihon Geka Hokan; 1991 Mar; 60(2):135-9. PubMed ID: 1819244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The complement system in the acute phase of myocardial infarction.
    Yasuda M; Kawarabayashi T; Akioka K; Teragaki M; Oku H; Kanayama Y; Takeuchi K; Takeda T; Kawase Y; Ikuno Y
    Jpn Circ J; 1989 Sep; 53(9):1017-22. PubMed ID: 2513427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus.
    Li H; Lin S; Yang S; Chen L; Zheng X
    Clin Rheumatol; 2015 Mar; 34(3):471-7. PubMed ID: 25597615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
    Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
    Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy.
    McAfee SL; Powell SN; Colby C; Spitzer TR
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):151-6. PubMed ID: 12007954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Level of complement activity and components C1, C4, C2, and C3 in complement response to bacterial challenge in malnourished rats.
    Sakamoto M; Ishii S; Nishioka K; Shimada K
    Infect Immun; 1981 May; 32(2):553-6. PubMed ID: 7251136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.
    Romano C; Del Mastro A; Sellitto A; Solaro E; Esposito S; Cuomo G
    Clin Rheumatol; 2018 Jun; 37(6):1695-1700. PubMed ID: 29362962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.
    Maeng CH; Ko YH; Lim DH; Kang ES; Choi JY; Kim WS; Kim SJ
    Cancer Res Treat; 2017 Jan; 49(1):92-103. PubMed ID: 27188204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody.
    Doi H; Matsushita T; Isobe N; Matsuoka T; Minohara M; Ochi H; Kira JI
    Mult Scler; 2009 Mar; 15(3):304-10. PubMed ID: 19028829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort.
    Ritchie RF; Palomaki GE; Neveux LM; Navolotskaia O; Ledue TB; Craig WY
    J Clin Lab Anal; 2004; 18(1):1-8. PubMed ID: 14730550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of antibody isotype on the activation of C3 and C4 by immune complexes formed in the presence of serum: correlation with the prevention of immune precipitation.
    Stewart WW; Johnson A; Steward MW; Whaley K; Kerr MA
    Mol Immunol; 1990 May; 27(5):423-8. PubMed ID: 2366759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis.
    Cojocaru M; Serbănescu A; Cojocaru IM
    Rom J Intern Med; 1993; 31(2):131-7. PubMed ID: 8268831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.